To hear about similar clinical trials, please enter your email below
Trial Title:
Cancer Survivorship in Hematologic Malignancies
NCT ID:
NCT05780411
Condition:
Cancer Survivors
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Cross-Sectional
Intervention:
Intervention type:
Other
Intervention name:
questionnaire
Description:
The symptom related checklist questionnaire, Quality of life questionnaire, Coping
strategies questionnaire, Distress thermometer
Arm group label:
Lymphoid group
Arm group label:
Myloid group
Summary:
General objective: to improve care for haematological cancer survivors. This study will
(i) Estimate the incidence of cancer survivor syndrome (CSS) in adult Egyptian patients
with haematological neoplasms (HN). (ii) Asses the risk factors of CSS in patients with
HN. (iii) Study the effect of CSS on quality of life in patients with HN. (iv) To explore
coping strategies of patients with HN having CSS
Detailed description:
According to the American Cancer Society the term cancer survivor refersto people who
have no signs of cancer after finishing treatment, people receiving extended treatment
over a longer period of time to control the cancer or reduce risk of its return, and
people with advanced cancer. Most hematologic malignancies (HM) are incurable and
typically follow unpredictable remitting-relapsing pathways associated with varying need
for treatment, which may be distressing for patients. Distress symptoms and psychological
disorders secondary to cancer have also been shown to have significant negative
consequences for both the patient and the family.
Maladaptive coping and abnormal illness behavior have been associated with psychiatric
conditions, with negative effects on adherence to treatment, health behavior, and quality
of life (Grassi et al 2017). Moreover, an increased length of stay in the hospital and/or
an increased time in rehabilitation have been found to be more common among patients
showing psychiatric symptoms, especially depression, than those with normal adjustment to
illness (Cordova et al 2017). Unfortunately, cancer-related distress is commonly
underrecognized and subsequently undertreated especially for patients with HM in
developing countries. Search in literature revealed several screening methods for the
psychological consequences of cancer such as Distress Thermometer , Symptom related
checklist questionnaire, Quality of life questionnaire, Coping strategies questionnaire.
Also, guidelines for the management of psychological distress have been developed by
several scientific cancer associations.
Criteria for eligibility:
Study pop:
Cancer survivor syndrome patients with haematological malignancy divided into two groups:
Group 1: Myeloid neoplasms. Group 2: Lymphoid neoplasms in remission. The questionnaires
will be collected from January 2023 to January 2025 in the Department of Hematology from
Assiut University Hospital. This study will be approved from the Committee on Human
Experimentation of Assiut University
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- a. Inclusion criteria:
1. Age will be more than or equal 18 years old regardless with six.
2. Patients have been clinically diagnosed with haematological cancers.
3. Being Native Egyptian patients.
Exclusion Criteria:
- History of psychiatric disorders. b) Having other concomitant haematological
diseases or solid neoplasm or relapse or other chronic disorders
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Locations:
Facility:
Name:
Assiut University
Address:
City:
Assiut
Zip:
71515
Country:
Egypt
Contact:
Last name:
Roaa M Saleh, MD
Phone:
00201010617778
Email:
roaasalh043@gmail.com
Contact backup:
Last name:
Zain E Ahmed, MD, PhD
Phone:
00201115596820
Email:
Drzain73@yahoo.com
Start date:
April 1, 2023
Completion date:
March 31, 2025
Lead sponsor:
Agency:
Assiut University
Agency class:
Other
Source:
Assiut University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05780411
